Post-Irradiation Morphea of the Breast in a Patient with Subacute Cutaneous Lupus Erythematosus: Case Report and a Literature Review

Carole Anouk Zahn, Laurence Feldmeyer, Roland Blum, Carlo Mainetti

Keywords: Morphea · Post-irradiation · Autoimmunity · Breast · Lupus erythematosus

Abstract
The appearance of morphea after radiotherapy, especially in the context of breast cancer, is a rare but known phenomenon. The incidence of post-irradiation morphea (PIM) of the breast is approximately one in every 500 patients, a higher rate than morphea of any other etiology, which is three per 100,000 per year. PIM usually appears less than 1 year after irradiation (range 1 month to 32 years). The histological pattern of PIM is different from the one in post-irradiation fibrosis, which is a common side effect of radiotherapy and usually appears during the first 3 months after irradiation. Several theories have been proposed to explain the pathogenesis of PIM, probably caused by a disturbance of the cytokine pattern. The development of PIM in patients with autoimmune diseases has been described in the literature. To our knowledge, we report the first case of PIM in a patient with subacute cutaneous lupus erythematosus. We should therefore pay attention when looking at patients with PIM to search for an underlying autoimmune disease.
**Introduction**

Radiation-induced morphea is a rare, but well-described, disfiguring disease with a negative impact on the patient’s quality of life [1]. Following the description of the first case in 1989 [2], other cases were reported, mostly in female patients after diagnosis of breast cancer. The development of PIM in patients with autoimmune diseases has been described in the literature [1, 3]. We present a case of post-irradiation morphea (PIM) of the breast in a patient with subacute cutaneous lupus erythematosus (SCLE) and a review of the literature.

**Case Report**

A 58-year-old woman developed reddish-papular infiltrated lesions on the upper back. An SCLE, characterized by erythematous annular patches and plaques on the trunk, was diagnosed based on the clinical presentation, the histological findings of lichenoid dermatitis, and positive anti-Ro/SSA antibodies (10.0 multiples of cutoff; normal <1.0). After treatment with hydroxychloroquine 200 mg twice daily and topical tacrolimus unguent, the skin lesions resolved rapidly. We reduced the daily dose to 200 mg daily and the disease remained in remission under treatment for the following 10 years.

At age of 68-year-old, the patient was operated on for a mucinous cancer of the left breast (27 mm, cT2, cN1sn [1/4], cM0, G3, ER 80%, PR 20%, Ki-67 15%, c-erB-2 score 0). The procedure was completed with an axillary lymphadenectomy, a radiotherapy (total dose 60 Gy), and a pharmacological treatment with letrozole and tamoxifen.

After 6 months, the patient developed an erythema of the left axillary region. The skin lesions on the left axillary region and lateral breast persisted for a year despite topical corticosteroid treatment. Histology showed interstitial granulomatous dermatitis. Clinical activity fluctuated over the next years between less and more inflammatory aspects, though never disappearing under topical corticosteroid treatment.

Six years after appearance of the axillary lesions, a novel induration appeared on the tumor scar. Reddish to slightly violaceous patches, which spared the nipple on the left breast, appeared simultaneously (Fig. 1). Histology showed a flattened epidermis, dermal edema with homogeneous and eosinophilic collagen fibers, and a scanty perivascular and diffuse infiltrate of lymphocytes and plasma cells, compatible with morphea (Fig. 2a, b). A tissue PCR testing and a serology for *Borrelia burgdorferi* were negative. The patient decided not to treat the morphea with any specific medication, except emollients and during the following 18 months, while the morphea persisted, the SCLE stayed in remission.

**Discussion**

The incidence of PIM of the breast is approximately one in every 500 patients, a higher rate than morphea of any other etiology, which is three per 100,000 per year [4]. PIM usually appears less than 1 year after irradiation (range 1 month to 32 years, according to the literature) [4, 5]. A PubMed search for cases of PIM published to date revealed 46 cases of female patients with breast cancer (Table 1) [4, 6–24]. The histological pattern of PIM is different from post-irradiation fibrosis, which is a common side effect of radiotherapy and usually appears during the first 3 months after irradiation [1]. Despite various hypotheses, the exact pathogenesis of morphea still remains unclear. It seems, however, that a disturbance of the cytokine pattern plays an important role in the development of the disease [1, 25–30]. Radiotherapy increases collagen synthesis, which boosts the secretion of Th2 cytokines...
Fig. 1. Reddish to slightly violaceous patches which spared the nipple on the left breast.

Fig. 2. **a** Histological overview of dermal fibrosis (HE) – magnification, ×40. **b** Histological detail of chronic dermatitis, numerous plasma cells, and a dermal fibrosis (HE) – magnification, ×200.
Table 1. Series of 47 case reports of radiation-induced morphea after breast carcinoma described in the literature with our case

| References                          | Cases, n | Publication year | Mean age of patients, years | Radiation dose, Gy | Latency period between radiation and skin disease onset, months | Auto-antibodies laboratory results | Treatment                                                                 |
|-------------------------------------|----------|------------------|-----------------------------|--------------------|---------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------|
| Colver et al. [2]                   | 7        | 1989             | 61                          | 43-59              | 18-120 (mean 42)                                              | NR                                | NR                                                                        |
| Forbes et al. [9]                   | 1        | 1989             | 57                          | NR                 | 1                                                             | ANA-                              | NR                                                                        |
| Robertson et al. [10]               | 2        | 1991             | 60                          | 50.4               | 8-11                                                          | NR                                | NR                                                                        |
| Trattner et al. [11]                | 1        | 1991             | 57                          | 50                 | <12                                                           | ANA+ (1/320)                      | NR                                                                        |
| Winkelmann et al. [12]              | 4        | 1993             | 68                          | 46-50              | 1-6                                                           | NR                                | NR                                                                        |
| Davis et al. [13]                   | 6        | 1996             | 52                          | 46-55              | <12                                                           | ANA-                              | Topical, intralesional and systemic CS therapy                             |
| Mayr et al. [14]                    | 1        | 1997             | NR                          | NR                 | <12                                                           | NR                                | NR                                                                        |
| Gollob et al. [15]                  | 1        | 1998             | 54                          | 42.5               | 4                                                             | NR                                | Topical CS                                                                 |
| Bleasal et al. [16]                 | 4        | 1999             | 60                          | 45-50.4            | <12                                                           | NR                                | Topical CS under occlusion                                                |
| Fischer et al. [17]                 | 1        | 1999             | 74                          | NR                 | 108                                                           | NR                                | Photopheresis with hyaluronidase and PUVA                                  |
| Schaffer et al. [26]                | 2        | 1999             | 65                          | 43-46              | 79-382                                                        | ANA+ (1/640) and ENA-             | 1st patient with topical CS and oral doxycycline; 2nd patient no treatment |
| Arden-Jones and Black [18]          | 1        | 2003             | 60                          | NR                 | 156                                                           | NR                                | Methotrexate 2.5 mg/week                                                   |
| Ullen and Björkholm [19]            | 1        | 2003             | 67                          | 50                 | <12                                                           | NR                                | NR                                                                        |
| Reddy et al. [20]                   | 1        | 2005             | 75                          | NR                 | <12                                                           | NR                                | Systemic CS                                                               |
| Dubner et al. [5]                   | 1        | 2006             | 52                          | 50.4               | 36                                                            | NR                                | Mastectomy refused from patient                                           |
| Dancio et al. [38]                  | 2        | 2006             | 60                          | NR                 | <12                                                           | NR                                | NR                                                                        |
| Seale et al. [21]                   | 1        | 2008             | 60                          | NR                 | 24                                                            | NR                                | NR                                                                        |
| Walsh et al. [8]                    | 5        | 2008             | 58                          | NR                 | 48-144                                                        | NR                                | Potent topical CS; other had mastectomy                                    |
| Cheah et al. [7]                    | 1        | 2008             | 69                          | NR                 | 9                                                             | NR                                | Topical and oral CS and PUVA                                              |
| Herrmann et al. [22]                | 1        | 2009             | 85                          | NR                 | 18                                                            | NR                                | NR                                                                        |
| Morgan rth et al. [23]              | 1        | 2010             | 64                          | NR                 | NR                                                            | NR                                | NR                                                                        |
| Alhathlool et al. [24]              | 1        | 2011             | 64                          | NR                 | 24                                                            | NR                                | Penicillin, topical calcipotriol, and UVA1 radiation                      |
| Our case                            | 1        | 2021             | 75                          | 60                 | 72                                                            | ANA+ (1/80), Anti-Ro/SSA+ (>240.0 U/mL) | Patient refused treatment                                                 |

NR, not reported; ANA, anti-nuclear antibodies; CS, corticosteroids; PUVA, psoralen and ultraviolet A radiation.
This phenomenon has already been described in animal models, where a TGF-b1 elevation and a significant skin fibrosis followed mice irradiation [28]. Also, human in vivo studies showed an indurated skin and a higher collagen production after irradiation compared with non-irradiated skin [29].

Besides genetic predisposition, prior viral infections (Epstein-Barr virus, varicella-zoster virus) and bacterial infections (*Borrelia burgdorferi*), as well as surgery or any other type of local trauma can trigger morphea [5]. Morphea occurs like psoriasis especially at “sites of trauma in a genetically predisposed person,” as defined by the isomorphic phenomenon of Koebner [31, 32]. Possible trauma also includes radiotherapy, which seen for itself in rare cases can increase the risk for development of skin tumors [33, 34]. Table 2 summarizes frequent possible secondary effects of radiotherapy on the skin.

Morphea coexists in some patients with underlying autoimmune diseases such as Hashimoto’s thyroiditis, vitiligo, primary biliary cirrhosis, autoimmune hepatitis, myasthenia gravis, or multiple sclerosis, mostly in the generalized and mixed subtypes with a higher prevalence among adults (29%) than children (3%) [32, 33, 35]. Besides extracutaneous manifestations such as arthritis, joint contractures, myositis, fasciitis, neurologic, ophthalmologic, and dental issues, half of the patients analyzed in the cohorts showed autoantibody positivity. The severity of the extracutaneous manifestations correlates with autoantibody titers [25]. Autoimmune diseases may predispose to morphea and PIM.

Due to the partially unclear pathogenesis, targeted treatment remains difficult. Some case reports suggest a “watch and wait” attitude, as the skin lesions may resolve spontaneously [36, 37]. In mild forms, topical or systemic steroid application in combination with methotrexate may already lead to an adequate benefit. In other cases, oral antibiotics, topical calcineurin inhibitors (tacrolimus), or imiquimod are required [7]. Phototherapy, especially psoralen and ultraviolet A radiation and UVA1, have shown a significant reduction of TGF-b, which led to a softening of the skin texture [6].

In conclusion, to our knowledge, we report the first case of PIM in a patient with SCLE.

### Statement of Ethics

Research complies with all ethical guidelines for human studies and animal welfare regulations. Ethical approval was not required for this study in accordance with local guidelines. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict of Interest Statement

The authors declare that there are no conflicts of interests to disclose.

Funding Sources

This manuscript did not receive any funding.

Author Contributions

Carole Anouk Zahn and Carlo Mainetti contributed to conception and design of the case report. Laurence Feldmeyer and Roland Blum performed the histological analysis. Carole Anouk Zahn wrote the first draft of the manuscript. Carole Anouk Zahn, Carlo Mainetti, Laurence Feldmeyer, and Roland Blum contributed to manuscript revision, read, and approved the submitted version.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article. Further inquiries can be directed to the corresponding author.

References

1 Spalek M, Jonska-Gmyrek J, Galecki J. Radiation-induced morphea: a literature review. J Eur Acad Dermatol Venereol. 2015 Feb;29(2):197–202.
2 Colver GB, Rodger A, Mortimer PS, Savin JA, Neill SM, Hunter JA. Post-irradiation morphea. Br J Dermatol. 1989;120:831–5.
3 Friedman O, Barnea Y, Hafner A. Underdiagnosed and disfiguring: radiation-induced morphea following breast cancer treatment. Breast. 2018 Jun;39:97–100.
4 Gonzalez-Ericsson PI, Estrada MV, Al-Rohil R, Sanders ME. Post-irradiation morphea of the breast: a case report and review of the literature. Histopathology. 2018 Jan;72(2):342–50.
5 Dubner S, Bovi J, White J, Susnik B. Postirradiation morphea in a breast cancer patient. Breast J. 2006;12:173–6.
6 Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54:440.
7 Cheah NL, Wong DW, Chetiyawardana AD. Radiation-induced morphea of the breast: a case report. J Med Case Rep. 2008;2:136.
8 Walsh N, Rheume D, Barnes P, Tremaine R, Reardon M. Postirradiation morphea: an underrecognized complication of treatment for breast cancer. Hum Pathol. 2008;39:1680–8.
9 Forbes AM, Woodrow JC, Verbov JL, Graham RM. Carcinoma of breast and scleroderma: four further cases and literature review. Br J Rheumatol. 1989;28:65–9.
10 Robertson JM, Clarke DH, Pezner MM, Matter RC. Breast conservation therapy. Severe breast fibrosis after radiation therapy in patients with collagen vascular disease. Cancer. 1991;68:502–8.
11 Trattner A, Figer A, David M, Lurie H, Sandbank M. Circumscribed scleroderma induced by postlumpectomy radiation therapy. Cancer. 1991;68:2131–3.
12 Winkelmann RK, Grad o GL, Quimby SR, Connolly SM. Pseudosclerodermatous panniculitis after irradiation: an unusual complication of mega voltage treatment of breast cancer. Mayo Clin Proc. 1993;68:122–7.
13 Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol. 1996;35:923–7.
14 Mayr NA, Riggs CE Jr, Saag KG, Wen BC, Pennington EC, Hussey DH. Mixed connective tissue disease and radiation toxicity. A case report. Cancer. 1997;79:612–8.
15 Gollob MH, Dekoven JG, Bell MJ, Assaad D, Rao J. Postirradiation morphea. J Rheumatol. 1998;25:2267–9.
16 Bleasel NR, Stapleton KM, Commens C, Abern VA. Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol. 1999;40:99–102.
17 Fischer M, Bormann G, Wohlrab J, Marsch WC. Radiation-induced morphea. Hautarzt. 1999;50:507–10.
18 Ardern-Jones MR, Black MM. Widespread morphea following radiotherapy for carcinoma of the breast. Clin Exp Dermatol. 2003;28:160–2.
19 Ullén H, Björkholm E. Localized scleroderma in a woman irradiated at two sites for endometrial and breast carcinoma: a case history and a review of the literature. Int J Gynaecol Cancer. 2003;13:77–82.
20 Reddy SM, Pui JC, Gold LI, Mitnick HJ. Postirradiation morphea and subcutaneous polyarteritis nodosa: case report and literature review. Semin Arthritis Rheum. 2005;34:728–34.
21 Scale M, Koh W, Henderson M, Drummond R, Cawson J. Imaging surveillance of the breast in a patient diagnosed with scleroderma after breast-conserving surgery and radiotherapy. Breast. 2008;14:79–81.
22 Herrmann T, Günther C, Csere P. Localized morphea: a rare but significant secondary complication following breast cancer radiotherapy. Case report and review of the literature on radiation reaction among patients with scleroderma/morphea. Strahlenther Onkol. 2009;185:603–7.
23 Morganroth PA, Dehoratius D, Curry H, Elenitsas R. Postirradiation morphea: a case report with a review of the literature and summary of clinicopathologic differential diagnosis. Am J Dermatopathol. 2010 May 24. Epub ahead of print.
24 Alhathlool A, Hein R, Andres C, Ring J, Eberlein B. Post-Irradiation Morphea: Case report and review of the literature. J Dermatol Case Rep. 2012 Sep 28;6(3):73–7.
25 Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K. Autoantibodies in morphea: an update. Front Immunol. 2019 Jul 9;10:1487.
26 Schaffer JV, Carroll C, Dworetzky I, Huether MJ, Girardi M. Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology. 2000;200:67–71.
27 Kawakami T, Ihn H, Xu W. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol. 1998;110:47–51.
28 Kumar S, Kolozsvary A, Kohl R, Lu M, Brown S, Kim JH. Radiation-induced skin injury in the animal model of scleroderma: implications for post-radiotherapy fibrosis. Radiat Oncol. 2008;3:40.
29 Illsley MC, Peacock JH, McNulty RJ, Yarnold JR. Increased collagen production in fibroblasts cultured from irradiated skin and effect of TGF 138, beta(1)- clinical study. Br J Cancer. 2000;83:650–4.
30 O’Brien JC, Rainwater YB, Malviya N, Cyrus N, Auer-Hackenberg L, Hyman LS, et al. Transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity in morphea. J Invest Dermatol. 2017;137:1663–70.
31 Rubin AI, Stiller MJ. A listing of skin conditions exhibiting the koebner and pseudo-koebner phenomena with eliciting stimuli. J Cutan Med Surg. 2002;6:29–34.
32 Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009 May;145(S):545–50.
33 Trefezer U, Milling A, Audring H, Sterry W. Malignant melanoma arising in radiotherapy eld: report of two cases and review of the literature. Dermatology. 2003;206:265–8.
34 de Giorgi V, Santì R, Grazzini M, Papì F, Gori A, Rossari S, et al. Synchronous angiosarcoma, melanoma and morphea of the breast skin 14 years after radiotherapy for mammary carcinoma. Acta Derm Venereol. 2010 May;90(3):283–6.
35 Machan A, Oumaliksh S, Khaledi M, Hjira N, Boui M. Radiation-induced morphea: autoimmunity as a risk factor. Neth J Med. 2019 Jan;77(1):29–31.
36 Wernicke AG, Goltzer Y, Trichter S, Sabbas A, Gaan J, Swistel AJ, et al. Morphoea as a consequence of accelerated partial breast irradiation. Clin Breast Cancer. 2011 Mar;11(1):67–70.
37 Sehgal VN, Srivastava G, Aggarwal AK, Behl PN, Choudhary M, Bajaj P. Localized scleroderma/morphea. Int J Dermatol. 2002;41:467–75.
38 Dancey AL, Waters RA. Morphea of the breast. Two case reports and discussion of the literature. J Plast Reconstr Aesthet Surg. 2006;59:1114–7.